RegeneRx Biopharmaceuticals, Inc. (RGRX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | -1.72 Million USD | 10.15% |
| 2021 | -1.92 Million USD | -9.71% |
| 2020 | -1.75 Million USD | -12.49% |
| 2019 | -1.55 Million USD | 21.87% |
| 2018 | -1.99 Million USD | -795.86% |
| 2017 | 286.48 Thousand USD | 25.04% |
| 2016 | 229.12 Thousand USD | 104.35% |
| 2015 | -5.27 Million USD | -91.4% |
| 2014 | -2.75 Million USD | -310.17% |
| 2013 | -671.34 Thousand USD | 20.74% |
| 2012 | -847 Thousand USD | 85.9% |
| 2011 | -6 Million USD | -19.57% |
| 2010 | -5.02 Million USD | 22.64% |
| 2009 | -6.49 Million USD | 38.95% |
| 2008 | -10.63 Million USD | 4.84% |
| 2007 | -11.17 Million USD | -35.21% |
| 2006 | -8.26 Million USD | -51.55% |
| 2005 | -5.45 Million USD | -63.99% |
| 2004 | -3.32 Million USD | -100.4% |
| 2003 | -1.65 Million USD | -18.18% |
| 2002 | -1.4 Million USD | -832.58% |
| 2001 | -150.6 Thousand USD | -114.46% |
| 2000 | 1.04 Million USD | 246.43% |
| 1999 | -711.23 Thousand USD | -140.37% |
| 1998 | 1.76 Million USD | 321.46% |
| 1997 | -795.43 Thousand USD | 51.38% |
| 1996 | -1.63 Million USD | 60.02% |
| 1995 | -4.09 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q1 | -545.78 Thousand USD | -39.63% |
| 2023 Q2 | - USD | 100.0% |
| 2023 Q3 | - USD | 0.0% |
| 2022 FY | -1.72 Million USD | 10.15% |
| 2022 Q1 | -423.99 Thousand USD | 5.69% |
| 2022 Q2 | -545.92 Thousand USD | -28.76% |
| 2022 Q3 | -366.47 Thousand USD | 32.87% |
| 2022 Q4 | -390.88 Thousand USD | -6.66% |
| 2021 Q2 | -338.63 Thousand USD | 10.81% |
| 2021 Q3 | -429.84 Thousand USD | -26.94% |
| 2021 FY | -1.92 Million USD | -9.71% |
| 2021 Q4 | -449.58 Thousand USD | -4.59% |
| 2021 Q1 | -379.69 Thousand USD | -3.21% |
| 2020 Q4 | -367.87 Thousand USD | -10.61% |
| 2020 FY | -1.75 Million USD | -12.49% |
| 2020 Q1 | -386.73 Thousand USD | -10.67% |
| 2020 Q2 | -436.16 Thousand USD | -12.78% |
| 2020 Q3 | -332.59 Thousand USD | 23.74% |
| 2019 Q3 | -333.9 Thousand USD | 14.04% |
| 2019 Q2 | -388.44 Thousand USD | -16.84% |
| 2019 Q1 | -332.45 Thousand USD | -26.01% |
| 2019 FY | -1.55 Million USD | 21.87% |
| 2019 Q4 | -349.44 Thousand USD | -4.65% |
| 2018 Q2 | -367.87 Thousand USD | 62.69% |
| 2018 Q3 | -375.98 Thousand USD | -2.21% |
| 2018 Q4 | -263.82 Thousand USD | 29.83% |
| 2018 FY | -1.99 Million USD | -795.86% |
| 2018 Q1 | -985.86 Thousand USD | -169.55% |
| 2017 Q4 | 1.41 Million USD | 204.33% |
| 2017 Q3 | -1.35 Million USD | -1247.71% |
| 2017 FY | 286.48 Thousand USD | 25.04% |
| 2017 Q1 | 109.34 Thousand USD | -74.09% |
| 2017 Q2 | 118.37 Thousand USD | 8.27% |
| 2016 Q3 | 861.67 Thousand USD | -62.93% |
| 2016 Q4 | 422.05 Thousand USD | -51.02% |
| 2016 Q1 | -3.37 Million USD | -411.77% |
| 2016 FY | 229.12 Thousand USD | 104.35% |
| 2016 Q2 | 2.32 Million USD | 168.79% |
| 2015 FY | -5.27 Million USD | -91.4% |
| 2015 Q4 | -660.23 Thousand USD | 41.55% |
| 2015 Q1 | -1.71 Million USD | -222.36% |
| 2015 Q3 | -1.12 Million USD | 35.89% |
| 2015 Q2 | -1.76 Million USD | -2.52% |
| 2014 Q1 | -2.12 Million USD | -23646.72% |
| 2014 Q2 | -218.78 Thousand USD | 89.7% |
| 2014 Q4 | -533.16 Thousand USD | -532.05% |
| 2014 FY | -2.75 Million USD | -310.17% |
| 2014 Q3 | 123.4 Thousand USD | 156.4% |
| 2013 Q3 | -99.8 Thousand USD | 56.64% |
| 2013 Q2 | -230.18 Thousand USD | 30.75% |
| 2013 Q1 | -332.4 Thousand USD | -239.66% |
| 2013 FY | -671.34 Thousand USD | 20.74% |
| 2013 Q4 | -8949.00 USD | 91.03% |
| 2012 Q2 | -225.69 Thousand USD | 47.39% |
| 2012 Q3 | -94.49 Thousand USD | 58.13% |
| 2012 Q4 | -97.86 Thousand USD | -3.57% |
| 2012 FY | -847 Thousand USD | 85.9% |
| 2012 Q1 | -428.95 Thousand USD | 50.16% |
| 2011 Q2 | -1.53 Million USD | 4.02% |
| 2011 FY | -6 Million USD | -19.57% |
| 2011 Q4 | -860.7 Thousand USD | 57.34% |
| 2011 Q3 | -2.01 Million USD | -31.69% |
| 2011 Q1 | -1.59 Million USD | -73.53% |
| 2010 Q1 | -1.14 Million USD | 10.38% |
| 2010 Q2 | -1.37 Million USD | -19.62% |
| 2010 Q3 | -1.58 Million USD | -15.86% |
| 2010 FY | -5.02 Million USD | 22.64% |
| 2010 Q4 | -919.91 Thousand USD | 42.07% |
| 2009 Q3 | -1.24 Million USD | 14.97% |
| 2009 Q4 | -1.27 Million USD | -3.0% |
| 2009 FY | -6.49 Million USD | 38.95% |
| 2009 Q2 | -1.45 Million USD | 41.95% |
| 2009 Q1 | -2.51 Million USD | 9.9% |
| 2008 Q3 | -2.37 Million USD | 16.99% |
| 2008 Q4 | -2.79 Million USD | -17.6% |
| 2008 FY | -10.63 Million USD | 4.84% |
| 2008 Q2 | -2.85 Million USD | -9.41% |
| 2008 Q1 | -2.61 Million USD | 26.2% |
| 2007 Q2 | -2.55 Million USD | 14.99% |
| 2007 Q4 | -3.54 Million USD | -70.1% |
| 2007 FY | -11.17 Million USD | -35.21% |
| 2007 Q1 | -3 Million USD | -91.34% |
| 2007 Q3 | -2.08 Million USD | 18.45% |
| 2006 Q1 | -1.32 Million USD | 39.6% |
| 2006 Q2 | -3.43 Million USD | -159.43% |
| 2006 FY | -8.26 Million USD | -51.55% |
| 2006 Q3 | -1.93 Million USD | 43.69% |
| 2006 Q4 | -1.56 Million USD | 18.92% |
| 2005 Q4 | -2.19 Million USD | -59.03% |
| 2005 FY | -5.45 Million USD | -63.99% |
| 2005 Q1 | -898.36 Thousand USD | -8.83% |
| 2005 Q2 | -983.41 Thousand USD | -9.47% |
| 2005 Q3 | -1.37 Million USD | -40.27% |
| 2004 Q4 | -825.46 Thousand USD | 15.77% |
| 2004 Q2 | -361.59 Thousand USD | 68.81% |
| 2004 Q1 | -1.15 Million USD | -127.09% |
| 2004 FY | -3.32 Million USD | -100.4% |
| 2004 Q3 | -980.03 Thousand USD | -171.03% |
| 2003 Q3 | -387.49 Thousand USD | 18.26% |
| 2003 FY | -1.65 Million USD | -18.18% |
| 2003 Q2 | -474.06 Thousand USD | -64.72% |
| 2003 Q1 | -287.8 Thousand USD | 39.18% |
| 2003 Q4 | -510.5 Thousand USD | -31.74% |
| 2002 Q1 | -119.92 Thousand USD | -10.45% |
| 2002 Q3 | -334.6 Thousand USD | 29.82% |
| 2002 FY | -1.4 Million USD | -832.58% |
| 2002 Q2 | -476.77 Thousand USD | -297.56% |
| 2002 Q4 | -473.23 Thousand USD | -41.43% |
| 2001 Q1 | 39.29 Thousand USD | 136.63% |
| 2001 FY | -150.6 Thousand USD | -114.46% |
| 2001 Q4 | -108.57 Thousand USD | -471.8% |
| 2001 Q3 | 29.2 Thousand USD | 126.42% |
| 2001 Q2 | -110.52 Thousand USD | -381.29% |
| 2000 FY | 1.04 Million USD | 246.43% |
| 2000 Q1 | 1.28 Million USD | 1512.23% |
| 2000 Q2 | -40.74 Thousand USD | -103.18% |
| 2000 Q3 | -91 Thousand USD | -123.35% |
| 2000 Q4 | -107.25 Thousand USD | -17.86% |
| 1999 Q1 | -377.35 Thousand USD | 0.0% |
| 1999 Q2 | -243.2 Thousand USD | 35.55% |
| 1999 Q3 | -243.2 Thousand USD | 0.0% |
| 1999 Q4 | -90.66 Thousand USD | 62.72% |
| 1999 FY | -711.23 Thousand USD | -140.37% |
| 1998 FY | 1.76 Million USD | 321.46% |
| 1997 FY | -795.43 Thousand USD | 51.38% |
| 1996 FY | -1.63 Million USD | 60.02% |
| 1995 FY | -4.09 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -29.356% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 75.261% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 103.261% |
| Nascent Biotech, Inc. | -2.08 Million USD | 17.255% |
| Rebus Holdings, Inc. | -1.02 Million USD | -69.358% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 102.652% |
| Qrons Inc. | -789.34 Thousand USD | -118.846% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -173.156% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 97.24% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -315.774% |
| Skye Bioscience, Inc. | -37.64 Million USD | 95.411% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 97.696% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 73.731% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -531.837% |
| SQZ Biotechnologies Company | -79.46 Million USD | 97.826% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 40.276% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 5.112% |
| Mesoblast Limited | -87.95 Million USD | 98.036% |
| Marizyme, Inc. | -65.34 Million USD | 97.356% |
| Genus plc | 7.9 Million USD | 121.867% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 84.14% |
| Pharming Group N.V. | -10.54 Million USD | 83.623% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 20.387% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 53.441% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 80.467% |
| ContraFect Corporation | -65.15 Million USD | 97.349% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 64.645% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| IMV Inc. | -36.48 Million USD | 95.265% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 78.567% |
| MultiCell Technologies, Inc. | -380.07 USD | -454409.696% |
| ONE Bio Corp. | 8.67 Million USD | 119.909% |
| Accustem Sciences Inc. | -3.74 Million USD | 53.891% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 96.658% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -36.328% |
| Q BioMed Inc. | -2.05 Million USD | 15.82% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 53.725% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 27.444% |
| Biomind Labs Inc. | -1.21 Million USD | -42.257% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 97.108% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 44.307% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 78.142% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 11.378% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -11434.822% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 89.116% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 70.305% |
| GB Sciences, Inc. | -1.36 Million USD | -26.862% |
| Alpha Cognition Inc. | -13.77 Million USD | 87.457% |
| HST Global, Inc. | -146.21 Thousand USD | -1081.489% |
| CSL Limited | 2.64 Billion USD | 100.065% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 1.557% |
| Halberd Corporation | -79.67 Thousand USD | -2068.1% |
| Enzolytics Inc. | -2.17 Million USD | 20.644% |
| Agentix Corp. | -1.37 Million USD | -25.705% |
| Resverlogix Corp. | -3.61 Million USD | 52.148% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 45.531% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.415% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 1862.709% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 124.947% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 56.52% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 42.915% |
| AVAX Technologies, Inc. | -6.41 Million USD | 73.066% |
| Zenith Capital Corp. | -10.59 Million USD | 83.697% |
| Genscript Biotech Corporation | -95.47 Million USD | 98.191% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -7332.471% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 58.334% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -2758.103% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 13.848% |
| Kadimastem Ltd | -3.3 Million USD | 47.77% |
| Helix BioMedix, Inc. | -1.05 Million USD | -63.576% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 54.767% |
| BioStem Technologies, Inc. | -8.48 Million USD | 79.636% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -291.386% |
| LadRx Corporation | 400.44 Thousand USD | 531.386% |
| Cell Source, Inc. | -5.32 Million USD | 67.536% |
| Regen BioPharma, Inc. | 1.02 Million USD | 268.778% |
| Regen BioPharma, Inc. | 1.02 Million USD | 268.778% |
| NovAccess Global Inc. | -4.76 Million USD | 63.779% |
| Affymax, Inc. | -14.42 Million USD | 88.024% |
| Itoco Inc. | -1.86 Million USD | 7.573% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 61.116% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -3.502% |
| Mobile Lads Corp. | -2.26 Million USD | 23.675% |
| CytoDyn Inc. | -49.84 Million USD | 96.534% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -2085.739% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -657.234% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -83.473% |
| SYBLEU INC | -180.3 Thousand USD | -858.079% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -7.113% |
| International Stem Cell Corporation | -131 Thousand USD | -1218.668% |
| Bioxytran, Inc. | -4.28 Million USD | 59.639% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -3082.958% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 31.728% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 96.407% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 18.285% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -121.217% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 45.472% |
| Neutra Corp. | -233.46 Thousand USD | -639.92% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 91.487% |
| PureTech Health plc | -65.69 Million USD | 97.371% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 91.877% |
| IXICO plc | -1.17 Million USD | -46.643% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 82.598% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 96.976% |
| CSL Limited | 2.64 Billion USD | 100.065% |
| Cellectis S.A. | -103.17 Million USD | 98.326% |